Atossa Therapeutics
ATOS
86 hedge funds and large institutions have $41.6M invested in Atossa Therapeutics in 2024 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 21 increasing their positions, 24 reducing their positions, and 7 closing their positions.
494% more call options, than puts
Call options by funds: $1M | Put options by funds: $169K
129% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 7
33% more capital invested
Capital invested by funds: $31.2M → $41.6M (+$10.4M)
12% more funds holding
Funds holding: 77 → 86 (+9)
0.06% more ownership
Funds ownership: 1.39% → 1.45% (+0.06%)
13% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$925K |
| 2 |
BlackRock
New York
|
+$633K |
| 3 |
Goldman Sachs
New York
|
+$197K |
| 4 |
Barclays
London,
United Kingdom
|
+$166K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$151K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$324K |
| 2 |
Jane Street
New York
|
-$166K |
| 3 |
Bank of New York Mellon
New York
|
-$145K |
| 4 |
Mariner
Overland Park,
Kansas
|
-$126K |
| 5 |
Two Sigma Investments
New York
|
-$116K |
ATOS Hedge Fund Activity: Q3 2024 in Review
86 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q3 2024, worth a combined $41.6M — up 33% from $31.2M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ATOS positions and 7 closed out — a net gain of 9 holders — while 21 added to existing stakes and 24 trimmed.
The largest buyer was Northern Trust, adding an estimated $925K. The largest seller was Renaissance Technologies, cutting an estimated $324K.
- 86 institutional investors held Atossa Therapeutics (ATOS) as of Q3 2024, up from 77 in Q2 2024.
- Funds reported $41.6M of Atossa Therapeutics stock for Q3 2024, up 33% quarter-over-quarter.
- 16 funds opened new Atossa Therapeutics positions in Q3 2024 and 7 closed out, a net change of +9 holders.
- The largest Atossa Therapeutics buyer in Q3 2024 was Northern Trust, an estimated $925K added.
- The largest Atossa Therapeutics seller in Q3 2024 was Renaissance Technologies, an estimated $324K sold.
Based on aggregated 13F filings for Q3 2024.